2025 Regular SessionKentucky Legislature

HB788: AN ACT relating to buprenorphine products.

Legislative Summary

Create a new section of KRS Chapter 311 to require that a dosage regimen for Buprenorphine-Mono-Product or Buprenorphine-Combined-with-Naloxone prescribed by a licensed physician to meet the treatment needs of a patient; require the Kentucky Board of Medical Licensure to promulgate administrative regulations to implement the requirement; create a new section of KRS Chapter 314 to require that a dosage regimen for Buprenorphine-Mono-Product or Buprenorphine-Combined-with-Naloxone prescribed by a licensed advanced practice registered nurse meet the treatment needs of a patient; require the Kentucky Board of Nursing to promulgate administrative regulations to implement the requirement.

Demographic Impact

Overall analysis of equity impact

90% Positive
High ConfidenceView detailed demographic breakdown ↓

Unlock Full Demographic Insights

Go beyond the overall score.

Gain a deeper understanding of this bill's potential impact across diverse communities, including detailed breakdowns by category and subgroup. Access to this granular analysis helps ensure equitable outcomes.

Enable full analysis features for your organization.

Contact Sales to Learn More

Or email us directly at sales@legiequity.us.

Bill History

2/19/2025
introduced in House
House of Representatives
2/19/2025
to Committee on Committees (H)
House of Representatives
2/26/2025
to Health Services (H)
House of Representatives
3/5/2025
taken from Health Services (H)
House of Representatives
3/5/2025
1st reading
House of Representatives
3/5/2025
returned to Health Services (H)
House of Representatives

Status Information

Current Status
Introduced(2/19/2025)
Chamber
House of Representatives
Committee
Health Services(House of Representatives)

Sponsors

Republican: 1
Democrat: 1

Documents

Introduced
Bill Text1/1/197020.6 KB